non-squamous non-small-cell lung cancer
Conditions
Interventions
Patients were given Bevacizumab(15mg/kg, div), Pemetrexed(500mg/m2, div) and Carboplatin(AUC=5, div) on day 1, every 4 weeks, up to 6 cycles. Patients who get efficacy above SD without unacceptable to
Sponsors
National Hospital Organization Hokkaido Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)histologically or cytologically confirmed non-squamous non-small-cell lung cancer 2)chemotheraoy naive patients or postoperative recurrence patients without adjuvant chemotherapy excluded UFT treatment 3) stage IIIB/IV(UICC-7) or postoperative recurrence patients 4)mesurrable leision 5)ECOG performance status of 0-2 6)age: 20-75 7)adequate major organ (hemoatologic hepatic, respiratory and renal function) function white blood cell >=3000/mm3 hemoglobin >=9.5g/dl platelet >=100000/mm3 total bilirubin <= 1.5 AST/ALT <=2.5 times upper limit of normal PaO2 >=65 torr or SpO2 >=92% 8)life expectancy more than 3 months 9)written informed consent
Exclusion criteria
Exclusion criteria: 1)Uncontrolled complication unstable angina or myocardiac infarction within 3 months uncontrolled DM and hypertension uncontrolled infection active interstitial pneumonia active gastiric ulcer active concominant cancer illeus 2)patients who cannot been given Bevacizumab with great vessel invasion cavity in tumor current or previous histoty ofhemoptysis(2.5ml)due to NSCLC receiving anticoagulant drug(except Aspirin under 325mg/day) untreated current brain metastasis 3)history of sever allergy 4)severe SVC syndrome 5)uncontrolled malignant pleuritis 6)history of pregnancy or lactation 7)Patients whose participation in the trial is judged to be inappropriate by the attending doctor
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| responce rate | — |
Secondary
| Measure | Time frame |
|---|---|
| safety, progression free survival, over all survival | — |
Countries
Japan
Contacts
Public Contactogura shigeaki
National Hospital Organization Hokkaido Medical Center Department of Respiratory Medicine
Outcome results
None listed